{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:31:50Z","timestamp":1780324310169,"version":"3.54.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["955756"],"award-info":[{"award-number":["955756"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejps.2025.107401","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:09:22Z","timestamp":1765037362000},"page":"107401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["High-throughput screening of amorphous solid dispersions: a systematic approach to enhance bioaccessibility of a poorly soluble drug"],"prefix":"10.1016","volume":"217","author":[{"given":"Malte B\u00f8gh","family":"Senniksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus Johann","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Saal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kuentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan T.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5085-6163","authenticated-orcid":false,"given":"Nicole","family":"Wyttenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejps.2025.107401_bib0002","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11095-009-0021-1","article-title":"Understanding the behavior of amorphous pharmaceutical systems during dissolution","volume":"27","author":"Alonzo","year":"2010","journal-title":"Pharm Res"},{"issue":"9","key":"10.1016\/j.ejps.2025.107401_bib0015","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.xphs.2015.10.008","article-title":"Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-State characterization, and aqueous solubilization of Biopharmaceutical Classification system class II drugs","volume":"105","author":"Baghel","year":"2016","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.ejps.2025.107401_bib0007","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1002\/jps.22197","article-title":"A classification system to assess the crystallization tendency of organic molecules from undercooled melts","volume":"99","author":"Baird","year":"2010","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.ejps.2025.107401_bib0031","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpb.2012.07.009","article-title":"Drug precipitation-permeation interplay: supersaturation in an absorptive environment","volume":"82","author":"Bevernage","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"10.1016\/j.ejps.2025.107401_bib0013","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/jps.21138","article-title":"Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state","volume":"97","author":"Bhugra","year":"2008","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.ejps.2025.107401_bib0008","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijpharm.2017.02.042","article-title":"Influence of preparation pathway on the glass forming ability","volume":"521","author":"Blaabjerg","year":"2017","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.ejps.2025.107401_bib0012","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijpharm.2018.01.013","article-title":"Is there a correlation between the glass forming ability of a drug and its supersaturation propensity?","volume":"538","author":"Blaabjerg","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ejps.2025.107401_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122120","article-title":"Role of surfactants in improving release from higher drug loading amorphous solid dispersions","volume":"625","author":"Correa-Soto","year":"2022","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.ejps.2025.107401_bib0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0378-5173(01)00891-2","article-title":"The mechanisms of drug release from solid dispersions in water-soluble polymers","volume":"231","author":"Craig","year":"2002","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.ejps.2025.107401_bib0029","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1208\/s12248-012-9337-6","article-title":"The solubility\u2013Permeability interplay and its implications in formulation design and development for poorly soluble drugs","volume":"14","author":"Dahan","year":"2012","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.ejps.2025.107401_bib0034","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jphp.13218","article-title":"Evaluating side-by-side diffusion models for studying drug supersaturation in an absorptive environment: a case example of fenofibrate and felodipine","volume":"72","author":"Eliasen","year":"2020","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"10.1016\/j.ejps.2025.107401_bib0044","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/17425247.2023.2298247","article-title":"Solubility-enabling formulations for oral delivery of lipophilic drugs: considering the solubility-permeability interplay for accelerated formulation development","volume":"21","author":"Fine-Shamir","year":"2024","journal-title":"Expert Opin Drug Del"},{"issue":"1","key":"10.1016\/j.ejps.2025.107401_bib0017","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijpharm.2013.04.040","article-title":"Highly efficient miniaturized coprecipitation screening (MiCoS) for amorphous solid dispersion formulation development","volume":"450","author":"Hu","year":"2013","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.ejps.2025.107401_bib0053","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1208\/s12249-017-0861-7","article-title":"Effects of the preparation process on the properties of amorphous solid dispersions","volume":"19","author":"Huang","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2025.107401_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106655","article-title":"Overcoming drug impurity challenges in amorphous solid dispersion with rational development of biorelevant dissolution-permeation method","volume":"192","author":"Huzjak","year":"2024","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"10.1016\/j.ejps.2025.107401_bib0043","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1021\/cg301679h","article-title":"Liquid\u2013liquid phase separation in highly supersaturated aqueous solutions of poorly water-soluble drugs: implications for solubility enhancing formulations","volume":"13","author":"Ilevbare","year":"2013","journal-title":"Cryst Growth Des"},{"issue":"3","key":"10.1016\/j.ejps.2025.107401_bib0024","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/acs.molpharmaceut.8b01261","article-title":"Insights into the dissolution mechanism of Ritonavir-Copovidone amorphous solid dispersions: importance of congruent release for enhanced performance","volume":"16","author":"Indulkar","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ejps.2025.107401_bib0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejpb.2023.04.026","article-title":"In vitro-in vivo relationship for amorphous solid dispersions using a double membrane dissolution-permeation setup","volume":"188","author":"J\u00f8rgensen","year":"2023","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"10.1016\/j.ejps.2025.107401_bib0036","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/pharmaceutics11050227","article-title":"High-throughput dissolution\/permeation screening -A 96-well two-compartment microplate approach","volume":"11","author":"Jacobsen","year":"2019","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.ejps.2025.107401_bib0005","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1211\/jpp.61.12.0001","article-title":"Review: physical chemistry of solid dispersions","volume":"61","author":"Janssens","year":"2009","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.ejps.2025.107401_bib0003","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.powtec.2015.05.012","article-title":"Amorphous formulations for dissolution and bioavailability enhancement of poorly soluble APIs","volume":"285","author":"Kanaujia","year":"2015","journal-title":"Powder Technol"},{"issue":"9","key":"10.1016\/j.ejps.2025.107401_bib0006","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/jps.23166","article-title":"Understanding the glass-forming ability of active pharmaceutical ingredients for designing supersaturating dosage forms","volume":"101","author":"Kawakami","year":"2012","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.ejps.2025.107401_bib0028","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1021\/acs.molpharmaceut.4c01140","article-title":"Mechanistic investigation into the phase separation behavior of Soluplus in the presence of biorelevant Media","volume":"22","author":"Lange","year":"2025","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ejps.2025.107401_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106957","article-title":"Exploration of solubilisation effects facilitated by the combination of Soluplus(R) with ionic surfactants","volume":"205","author":"Lange","year":"2025","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ejps.2025.107401_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114478","article-title":"A unifying approach to drug-in-polymer solubility prediction: streamlining experimental workflow and analysis","volume":"203","author":"Larsen","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"10.1016\/j.ejps.2025.107401_bib0009","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ejps.2013.03.016","article-title":"Early drug development predictions of glass-forming ability and physical stability of drugs","volume":"49","author":"Mahlin","year":"2013","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.ejps.2025.107401_bib0010","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1021\/mp100339c","article-title":"Toward in silico prediction of glass-forming ability from molecular structure alone: a screening tool in early drug development","volume":"8","author":"Mahlin","year":"2011","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.ejps.2025.107401_bib0054","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.xphs.2017.07.001","article-title":"Producing amorphous solid dispersions via Co-precipitation and spray drying: impact to physicochemical and biopharmaceutical properties","volume":"107","author":"Mann","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejps.2025.107401_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124727","article-title":"Comparison of in vitro screening methods for evaluating the effects of pharmaceutical excipients on membrane permeability","volume":"665","author":"Morita","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ejps.2025.107401_bib0001","article-title":"Trends in amorphous solid dispersion drug products approved by the U.S. Food and Drug Administration between 2012 and 2023","volume":"7","author":"Moseson","year":"2024","journal-title":"Int J Pharm X"},{"issue":"5","key":"10.1016\/j.ejps.2025.107401_bib0018","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s11095-021-03040-w","article-title":"Solvent-casted films to assist polymer selection for amorphous solid dispersions during preclinical studies: in-vitro and In-vivo exploration","volume":"38","author":"Mosquera-Giraldo","year":"2021","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.ejps.2025.107401_bib0014","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jps.23031","article-title":"Assessing the performance of amorphous solid dispersions","volume":"101","author":"Newman","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejps.2025.107401_bib0032","article-title":"In vitro dissolution\/permeation tools for amorphous solid dispersions bioavailability forecasting II: comparison and mechanistic insights","volume":"188","author":"Nunes","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ejps.2025.107401_bib0019","series-title":"Formulating Poorly Water Soluble Drugs","first-page":"287","article-title":"Structured development approach for amorphous systems","author":"Page","year":"2022"},{"issue":"10","key":"10.1016\/j.ejps.2025.107401_bib0046","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1016\/j.xphs.2016.06.016","article-title":"Studying the propensity of compounds to supersaturate: a practical and broadly applicable approach","volume":"105","author":"Palmelund","year":"2016","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.ejps.2025.107401_bib0045","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1007\/s11095-015-1712-4","article-title":"Impact of solubilizing additives on supersaturation and membrane transport of drugs","volume":"32","author":"Raina","year":"2015","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.ejps.2025.107401_bib0037","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.xphs.2018.03.030","article-title":"A refined developability classification system","volume":"107","author":"Rosenberger","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejps.2025.107401_bib0023","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2019.01.039","article-title":"Congruent release of drug and polymer: a \"sweet spot\" in the dissolution of amorphous solid dispersions","volume":"298","author":"Saboo","year":"2019","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.ejps.2025.107401_bib0022","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1021\/acs.molpharmaceut.9b01272","article-title":"Congruent release of drug and polymer from amorphous solid dispersions: insights into the role of drug-polymer hydrogen bonding, surface crystallization, and glass transition","volume":"17","author":"Saboo","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ejps.2025.107401_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105514","article-title":"Patterns of drug release as a function of drug loading from amorphous solid dispersions: a comparison of five different polymers","volume":"155","author":"Saboo","year":"2020","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"10.1016\/j.ejps.2025.107401_bib0055","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1248\/cpb.c12-00354","article-title":"Influence of manufacturing factors on physical stability and solubility of solid dispersions containing a low glass transition temperature drug","volume":"60","author":"Sakurai","year":"2012","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"1","key":"10.1016\/j.ejps.2025.107401_bib0004","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/10717544.2019.1704940","article-title":"Mechanisms of increased bioavailability through amorphous solid dispersions: a review","volume":"27","author":"Schittny","year":"2020","journal-title":"Drug Deliv"},{"key":"10.1016\/j.ejps.2025.107401_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107130","article-title":"Combining high-throughput ASD screening with the rDCS to streamline development of poorly soluble drugs","volume":"211","author":"Senniksen","year":"2025","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.ejps.2025.107401_bib0026","first-page":"1","article-title":"Mechanistic insights into amorphous solid dispersions: bridging theory and practice in drug delivery","volume":"42","author":"Srividya","year":"2025","journal-title":"Pharm Res"},{"issue":"7","key":"10.1016\/j.ejps.2025.107401_bib0049","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1021\/acs.molpharmaceut.7b00338","article-title":"Impact of drug-rich colloids of itraconazole and HPMCAS on membrane flux in vitro and oral bioavailability in rats","volume":"14","author":"Stewart","year":"2017","journal-title":"Mol Pharm"},{"issue":"33","key":"10.1016\/j.ejps.2025.107401_bib0011","doi-asserted-by":"crossref","first-page":"9974","DOI":"10.1021\/jp504450h","article-title":"Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds","volume":"118","author":"Trasi","year":"2014","journal-title":"J Phys Chem B"},{"issue":"1","key":"10.1016\/j.ejps.2025.107401_bib0050","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.xphs.2024.06.017","article-title":"Impact of colloidal drug-rich droplet size and amorphous solubility on drug membrane permeability: a comprehensive analysis","volume":"114","author":"Ueda","year":"2025","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.ejps.2025.107401_bib0027","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1021\/acs.molpharmaceut.8b00633","article-title":"Aggregation of hydroxypropyl methylcellulose acetate succinate under its dissolving pH and the impact on drug supersaturation","volume":"15","author":"Wang","year":"2018","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.ejps.2025.107401_bib0016","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3109\/1061186X.2010.525652","article-title":"Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: a mechanistic basis for utility","volume":"18","author":"Warren","year":"2010","journal-title":"J Drug Target"},{"key":"10.1016\/j.ejps.2025.107401_bib0040","article-title":"The shelf life of ASDs: 2. Predicting the shelf life at storage conditions","volume":"6","author":"Wolbert","year":"2023","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.ejps.2025.107401_bib0038","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejpb.2016.11.031","article-title":"Glass-forming ability of compounds in marketed amorphous drug products","volume":"112","author":"Wyttenbach","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"10.1016\/j.ejps.2025.107401_bib0033","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s11095-006-9205-0","article-title":"Miniaturized assay for solubility and residual solid screening (SORESOS) in early drug development","volume":"24","author":"Wyttenbach","year":"2007","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.ejps.2025.107401_bib0020","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ejpb.2013.01.009","article-title":"Miniaturized screening of polymers for amorphous drug stabilization (SPADS): rapid assessment of solid dispersion systems","volume":"84","author":"Wyttenbach","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"10.1016\/j.ejps.2025.107401_bib0048","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1021\/acs.molpharmaceut.3c01078","article-title":"Quantitative investigation of intestinal drug absorption enhancement by drug-rich nanodroplets generated via liquid\u2013Liquid phase separation","volume":"21","author":"Yoshikawa","year":"2024","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.ejps.2025.107401_bib0041","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1208\/s12248-016-9972-4","article-title":"Utilizing In vitro dissolution-permeation chamber for the quantitative prediction of pH-dependent drug-drug interactions with acid-reducing agents: a comparison with physiologically based pharmacokinetic modeling","volume":"18","author":"Zhu","year":"2016","journal-title":"AAPS J"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:30:09Z","timestamp":1773894609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725003987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"alternative-id":["S0928098725003987"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107401","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-throughput screening of amorphous solid dispersions: a systematic approach to enhance bioaccessibility of a poorly soluble drug","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107401"}}